- Home
- AGMB
as of 10-22-2026 3:56pm EST
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
| Founded: | 2017 | Country: | Belgium |
| Employees: | N/A | City: | N/A |
| Market Cap: | 576.2M | IPO Year: | 2024 |
| Target Price: | $37.67 | AVG Volume (30 days): | 114.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $7.92 - $17.82 | Next Earning Date: | 11-14-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered AGMB Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of AgomAb Therapeutics NV American Depositary Shares (AGMB)
Director
Avg Cost/Share
$8.88
Shares
10,000
Total Value
$88,800.00
Owned After
25,000
Director
Avg Cost/Share
$8.90
Shares
5,000
Total Value
$44,500.00
Owned After
25,000
SEC Form 4
Director
Avg Cost/Share
$8.70
Shares
5,000
Total Value
$43,500.00
Owned After
25,000
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$8.59
Shares
10,000
Total Value
$85,940.00
Owned After
10,000
Chief Executive Officer
Avg Cost/Share
$8.70
Shares
5,000
Total Value
$43,500.00
Owned After
21,823
SEC Form 4
Director
Avg Cost/Share
$8.57
Shares
5,000
Total Value
$42,850.00
Owned After
25,000
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$8.48
Shares
6,000
Total Value
$50,880.00
Owned After
21,823
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Epstein David R | AGMB | Director | Oct 21, 2026 | Buy | $8.88 | 10,000 | $88,800.00 | 25,000 | |
| Epstein David R | AGMB | Director | Oct 8, 2026 | Buy | $8.90 | 5,000 | $44,500.00 | 25,000 | |
| Epstein David R | AGMB | Director | Oct 6, 2026 | Buy | $8.70 | 5,000 | $43,500.00 | 25,000 | |
| Kemula Pierre Thadee Victor | AGMB | Chief Financial Officer | Oct 6, 2026 | Buy | $8.59 | 10,000 | $85,940.00 | 10,000 | |
| Knotnerus Tim Jasper | AGMB | Chief Executive Officer | Oct 6, 2026 | Buy | $8.70 | 5,000 | $43,500.00 | 21,823 | |
| Epstein David R | AGMB | Director | Oct 5, 2026 | Buy | $8.57 | 5,000 | $42,850.00 | 25,000 | |
| Knotnerus Tim Jasper | AGMB | Chief Executive Officer | Oct 5, 2026 | Buy | $8.48 | 6,000 | $50,880.00 | 21,823 |
Compare AGMB vs Leading Stocks
See how AGMB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AGMB AgomAb Therapeutics NV American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.